Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18822733 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | September 2024 | December 2025 | Allow | 15 | 2 | 0 | No | No |
| 18809625 | PSMA Imaging Agents | August 2024 | December 2025 | Allow | 16 | 2 | 0 | Yes | No |
| 18760458 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | July 2024 | June 2025 | Allow | 11 | 1 | 0 | No | No |
| 18665923 | FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITY | May 2024 | June 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18662947 | INHIBITORS OF BUNYAVIRIDAE AND USES THEREOF | May 2024 | March 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18659052 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | May 2024 | June 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18657963 | THERAPEUTIC COMPOUNDS AND METHODS | May 2024 | July 2025 | Allow | 14 | 2 | 0 | No | No |
| 18640607 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | April 2024 | May 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18618511 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | March 2024 | September 2025 | Allow | 17 | 1 | 1 | No | No |
| 18596521 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | March 2024 | December 2025 | Allow | 21 | 2 | 1 | No | No |
| 18587753 | NOVEL SMALL MOLECULE COMPOUND | February 2024 | April 2025 | Allow | 13 | 1 | 0 | No | No |
| 18587730 | CARDIAC SARCOMERE INHIBITORS | February 2024 | October 2024 | Allow | 7 | 0 | 0 | No | No |
| 18435744 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | February 2024 | April 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18433950 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | February 2024 | February 2025 | Allow | 13 | 1 | 0 | No | No |
| 18429524 | METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | February 2024 | February 2025 | Abandon | 13 | 0 | 1 | No | No |
| 18413175 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | January 2024 | August 2024 | Allow | 7 | 0 | 0 | No | No |
| 18409042 | CARRIER-FREE CURCUMIN NANOPARTICLES FOR EGFR-POSITIVE CANCER THERAPY | January 2024 | June 2025 | Allow | 17 | 0 | 1 | No | No |
| 18404478 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | January 2024 | April 2025 | Allow | 16 | 2 | 0 | Yes | No |
| 18538176 | Boronated Multifunctional Targeting Drug Conjugates, Their Uses and Methods for Their Preparation | December 2023 | March 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18524807 | AZABICYCLO AND DIAZEPINE DERIVATIVES | November 2023 | October 2024 | Allow | 11 | 1 | 0 | No | No |
| 18510936 | AMINATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | November 2023 | March 2025 | Allow | 16 | 3 | 1 | Yes | No |
| 18388728 | {5-CHLORO-2-(2-(3-(SUBSTITUTEDPHENYL)-1,2,4-OXADIAZOL-5-YL)ETHYL)PHENYL}(PHENYL)METHANONES AS LARVICIDAL AGENTS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18505713 | CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | November 2023 | January 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18386561 | 3-(4-NITROPHENYL)-5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUND | November 2023 | February 2024 | Allow | 3 | 0 | 0 | No | No |
| 18473796 | METHODS FOR CANCER THERAPY | September 2023 | October 2025 | Allow | 24 | 2 | 0 | No | No |
| 18472147 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | September 2023 | April 2025 | Allow | 19 | 2 | 0 | No | No |
| 18466804 | COMPOSITIONS AND DEVICES OF POLY-4-HYDROXYBUTYRATE | September 2023 | May 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18460337 | HEPATITIS B CORE PROTEIN MODULATORS | September 2023 | December 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18272884 | METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 3-(2-CHLOROTHIAZOL-5-YL)-8-METHYL-7-OXO-6-PHENYL-2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM-5-OLATE | July 2023 | October 2025 | Allow | 27 | 0 | 0 | No | No |
| 18260951 | PROCESS FOR CRYSTALLIZING NALMEFENE HYDROCHLORIDE | July 2023 | March 2026 | Allow | 32 | 0 | 0 | No | No |
| 18259944 | COMPOSITION FOR INHIBITING GROWTH OF CANCER STEM CELLS | June 2023 | February 2026 | Allow | 32 | 1 | 0 | Yes | No |
| 18343554 | LYMPH DIRECTING PRODRUGS | June 2023 | February 2025 | Abandon | 20 | 2 | 1 | No | No |
| 18334426 | DIEPOXY COMPOUND, CURABLE COMPOSITION, CURED PRODUCT, AND OPTICAL MEMBER | June 2023 | November 2025 | Allow | 29 | 0 | 0 | No | No |
| 18254010 | METHOD OF PREPARING HETEROGENEOUS LINEAR CARBONATE USING AMINE-BASED COMPOUND CATALYST | May 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18321092 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | May 2023 | August 2024 | Allow | 14 | 1 | 0 | No | No |
| 18199205 | SOLABEGRON ZWITTERION AND USES THEREOF | May 2023 | June 2025 | Allow | 25 | 1 | 0 | No | No |
| 18314745 | DUAL-ACTING PHARMACEUTICAL COMPOSITIONS BASED ON SUPERSTRUCTURES OF ANGIOTENSIN RECEPTOR ANTAGONIST/BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | May 2023 | December 2025 | Abandon | 31 | 2 | 1 | No | No |
| 18031597 | COORDINATION COMPOUND AND LIGHT ABSORBER COMPRISING SAME | April 2023 | March 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18025579 | SYNTHESIS METHOD FOR PREPARING SGLT INHIBITOR INTERMEDIATE | March 2023 | August 2025 | Allow | 29 | 0 | 0 | No | No |
| 18181046 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | March 2023 | July 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18176571 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF | March 2023 | May 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18043491 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | February 2023 | January 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18172690 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | February 2023 | July 2024 | Allow | 17 | 3 | 1 | Yes | No |
| 18042036 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | February 2023 | October 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 18111241 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | February 2023 | June 2024 | Allow | 16 | 1 | 0 | No | No |
| 17908576 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | February 2023 | February 2026 | Allow | 41 | 1 | 0 | Yes | No |
| 18041593 | PROCESS FOR THE PREPARATION OF PYRIDAZINONE DERIVATIVES | February 2023 | March 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18020013 | KRAS G12D INHIBITORS | February 2023 | February 2026 | Allow | 36 | 1 | 1 | No | No |
| 18019655 | Low-Dose Ophthalmic Compositions and Methods | February 2023 | January 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18158356 | BENZONORBORNADIENE DERIVATIVES AND REACTIONS THEREOF | January 2023 | August 2025 | Abandon | 31 | 2 | 1 | No | No |
| 18156316 | PYRAZINOIC ACID CONJUGATES AND HYBRID CONJUGATES | January 2023 | January 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18016532 | CODRUG THAT DISINTEGRATES IN INTESTINE, PREPARATION THEREFOR, AND USE THEREOF | January 2023 | February 2026 | Allow | 37 | 0 | 1 | No | No |
| 18095971 | NOVEL PREPARATION CONTAINING BENZIMIDAZOLE DERIVATIVE | January 2023 | February 2026 | Abandon | 37 | 2 | 1 | No | No |
| 18011469 | CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS COMPRISING 2 OR MORE ARYL OR HETEROARYL CONNECTED VIA LINKER AND USE THEREOF | December 2022 | February 2026 | Allow | 37 | 1 | 1 | No | No |
| 18081409 | ENERGETIC COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | December 2022 | October 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 18065237 | POLYMERIZABLE FUSED TRICYCLIC COMPOUNDS AS ABSORBERS OF UV AND VISIBLE LIGHT | December 2022 | December 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 18064206 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | December 2022 | February 2024 | Allow | 14 | 1 | 0 | No | No |
| 18009637 | USE OF INHIBITORS OF THE ACTIVATOR PROTEIN 1 (AP-1) FOR PREVENTING ADHESIONS | December 2022 | March 2026 | Allow | 39 | 1 | 1 | No | No |
| 18073644 | FLUORESCENT COMPOUND FOR IMMUNOHISCHEMISTRY AND DIAGNOSIS COMPOSITION FOR DETECTING BIOLOGICAL MATERIAL COMPRISING THE SAME | December 2022 | March 2026 | Allow | 39 | 1 | 0 | No | No |
| 18072505 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | November 2022 | August 2023 | Allow | 9 | 0 | 0 | No | No |
| 18072501 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | November 2022 | August 2023 | Allow | 9 | 0 | 0 | No | No |
| 17990656 | ANTIFUNGAL AGENTS WITH ENHANCED ACTIVITY IN ACIDIC PH | November 2022 | December 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17925221 | PHARMACEUTICAL COMPOSITION IN WHICH PRODUCTION OF IMPURITIES IS SUPPRESSED | November 2022 | December 2025 | Allow | 37 | 0 | 0 | No | No |
| 17985531 | CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | November 2022 | July 2023 | Allow | 8 | 0 | 0 | No | No |
| 17924505 | METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | November 2022 | December 2025 | Allow | 37 | 1 | 0 | No | No |
| 17977960 | SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME | October 2022 | July 2024 | Allow | 21 | 1 | 0 | No | No |
| 17973362 | PHARMACEUTICAL COMPOSITIONS | October 2022 | January 2025 | Allow | 26 | 2 | 0 | No | No |
| 18049200 | DOSING OF VIBEGRON FOR TREATMENT OF OVERACTIVE BLADDER | October 2022 | November 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17996847 | TRIAZINANES POSSESSING THIOSULFONATE END-GROUPS AND METHODS OF MAKING THEM | October 2022 | September 2025 | Allow | 35 | 1 | 0 | No | No |
| 17996773 | ETHOXY/PROPOXY MODIFIED PYRAZOLINE ORGANIC MATTER, APPLICATION THEREOF, PHOTOCURABLE COMPOSITION, AND PHOTORESIST | October 2022 | January 2026 | Allow | 39 | 2 | 0 | No | No |
| 17920315 | Antiviral Agents, Uses Thereof and Methods for Their Preparation | October 2022 | February 2026 | Allow | 39 | 1 | 1 | Yes | No |
| 17919202 | NOVEL THERAPEUTIC USE OF PLEUROMUTILINS | October 2022 | January 2026 | Abandon | 39 | 2 | 0 | No | No |
| 17964003 | INHIBITORS OF OXIDIZED LOW-DENSITY LIPOPROTEIN RECEPTOR 1 AND METHODS OF USE THEREOF | October 2022 | February 2025 | Abandon | 28 | 2 | 1 | No | No |
| 17995920 | HYDROGENATION OF NEPETALACTONE | October 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17960199 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | October 2022 | February 2024 | Allow | 16 | 1 | 0 | No | No |
| 17937841 | INHIBITORS OF HEPATITIS B VIRUS | October 2022 | April 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17953622 | N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | September 2022 | February 2023 | Allow | 5 | 0 | 0 | Yes | No |
| 17907179 | PHARMACEUTICAL FORMULATIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | September 2022 | November 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17912427 | N-ACYLHYDRAZONIC COMPOUNDS, USE IN THE TREATMENT OF AMYLOID AND NON-AMYLOID DEGENERATIVE AGGREGOPATHIES, AND PHARMACEUTICAL COMPOSITION | September 2022 | January 2026 | Allow | 40 | 2 | 0 | No | No |
| 17906340 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | September 2022 | January 2026 | Allow | 40 | 2 | 0 | Yes | Yes |
| 17941959 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | September 2022 | October 2023 | Allow | 13 | 0 | 0 | No | No |
| 17820629 | PRODRUGS, ANALOGS OR DERIVATIVES OF KAEMPFEROL AS ANTIVIRAL AGENTS | August 2022 | June 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17797884 | PROBE FOR DETECTION OF CATHEPSIN ACTIVITY | August 2022 | April 2025 | Allow | 32 | 0 | 0 | No | No |
| 17881044 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | August 2022 | September 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17880996 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | August 2022 | June 2024 | Abandon | 23 | 2 | 1 | No | No |
| 17877514 | TARGETED THERAPEUTICS | July 2022 | April 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17813152 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | July 2022 | March 2025 | Allow | 32 | 0 | 1 | No | No |
| 17792837 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | July 2022 | July 2025 | Allow | 36 | 1 | 0 | No | No |
| 17862963 | THERAPEUTIC COMPOUNDS AND METHODS | July 2022 | February 2024 | Allow | 19 | 1 | 1 | No | No |
| 17862117 | SULCARDINE SALTS | July 2022 | November 2025 | Allow | 40 | 1 | 1 | No | No |
| 17790798 | SUBSTITUTED TRIAZINE COMPOUNDS AND USES THEREOF | July 2022 | January 2026 | Abandon | 42 | 1 | 1 | No | No |
| 17787543 | ISOBUTYRATE ESTER COMPOUND HAVING CARBONATE GROUP AT ALPHA-POSITION, AND FRAGRANCE COMPOSITION | June 2022 | November 2025 | Allow | 40 | 2 | 0 | Yes | No |
| 17786607 | TRPML MODULATORS | June 2022 | February 2026 | Allow | 44 | 3 | 1 | No | No |
| 17786089 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | June 2022 | October 2024 | Allow | 28 | 0 | 0 | No | No |
| 17807057 | BICYCLIC COMPOUNDS | June 2022 | December 2023 | Allow | 18 | 1 | 1 | No | No |
| 17780611 | (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5] OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION | May 2022 | July 2025 | Allow | 38 | 1 | 0 | No | No |
| 17744806 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | May 2022 | November 2023 | Allow | 18 | 1 | 0 | No | No |
| 17736895 | CARDIAC SARCOMERE INHIBITORS | May 2022 | July 2023 | Allow | 14 | 0 | 0 | No | No |
| 17734377 | PYRIDINIUM DERIVATIVES MADE BY HYDROTHERMAL SYNTHESIS FOR USE AS ANOLYTES IN ELECTROCHEMICAL CELLS | May 2022 | December 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17733891 | Myeloperoxidase Imaging Agents | April 2022 | October 2025 | Allow | 42 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner OTTON, ALICIA L.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner OTTON, ALICIA L works in Art Unit 1699 and has examined 477 patent applications in our dataset. With an allowance rate of 81.8%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 29 months.
Examiner OTTON, ALICIA L's allowance rate of 81.8% places them in the 53% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by OTTON, ALICIA L receive 1.83 office actions before reaching final disposition. This places the examiner in the 42% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by OTTON, ALICIA L is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +15.8% benefit to allowance rate for applications examined by OTTON, ALICIA L. This interview benefit is in the 56% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 26.7% of applications are subsequently allowed. This success rate is in the 45% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 75% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 71.4% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 92.6% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 9.4% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.2% of allowed cases (in the 86% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.